ARTICLE | Clinical News
Protalix preclinical data
July 22, 2013 7:00 AM UTC
Protalix said PRX-110 showed improved enzyme kinetics, less sensitivity to inhibition by actin and improved ex vivo efficacy in sputum from CF patients vs. Pulmozyme dornase alfa. The company plans ...